Home > Signal Pathway > AMQUAR单克隆抗体抑制剂 > AMQUAR 单克隆抗体抑制剂

AMQUAR 单克隆抗体抑制剂


  • alirocumab MA1008

    More

  • Alemtuzumab MA1007

    More

  • Adalimumab MA1006

    More

  • atezolizumab MA1009

    Atezolizumab (MPDL3280A), a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1, was approved for the treatment of platinum-resistant metastatic non-small cell lung cancer (NSCLC) and cisplatin-resistant bladder cancer.

    More

  • avelumab  MA1010

    Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has demonstrated clinical activity with a range of human cancers and has been approved for the treatment of Merkel cell and bladder carcinoma.

    More
    • Current page7, Total Pages8, Total Record38 First Prev 45678 Next Last Goto
More